FLT3 and acute myeloid leukemia: NPM1/cohesin-mut AML showed decreased sensitivity to the Aurora kinase A inhibitor MLN8054 and the FLT3/JAK inhibitor Midostaurin but responded better to SYK, MET, and EGFR inhibitors (Entospletinib, JNJ-38877605, Crizotinib, Foretinib, Lapatinib, Pelitinib, Fig. 6E).